Best Practices in NSCLC Molecular Testing, Part I

For High-Definition, Click

Alan B. Sandler, MD, begins the conversation on the best practices and guidelines in non-small cell lung cancer (NSCLC) by saying that he tests all tumors by the Sequenom System or Ion Torrent. For practice purposes, Sandler suggests following NCCN guidelines, which is to test all patients for the EGFR mutation and EML4-ALK, regardless of smoking history.

Mark A. Socinski, MD, echoes Sandler and adds that actionable molecular findings are EGFR mutations and EML4-ALK translocations. In his practice, Socinski also tests for BRAF, KRAS, and RET to identify patients for clinical trials; however a drug for those subsets is not currently approved.

Corey J. Langer, MD, comments on the amount and quality of a core biopsy. He says that while the amount of tissue matters, the cellularity of the tissue is more important.

Anne S. Tsao, MD, says that, in the right hands, risk to the patient is minimalized with CT-guided interventional core biopsies of the lung. In addition, endobronchial-guided, ultrasound-guided biopsies are becoming standard practice and good tissue can be biopsied from the mediastinum. Tsao says she will not do bone biopsies as it’s difficult to get enough tumor tissue.

View Part II of the discussion

Related Videos
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Benjamin Levy, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine